Researchers at Washington University in St. Louis have used click chemistry to link a second antibody to a pre-existing antibody-drug conjugate (ADC) in vivo. In preclinical models of HER2 and EGFR co-expressing pancreatic, breast and gastric tumors, sequential administration of the ADC and the second antibody was better at shrinking tumors than either ADC monotherapy or a combination of antibody and ADC treatment. Read More
In a recently published study, researchers from the Institute of Biomedical Research of Salamanca and collaborators investigated the potential of CD98hc as a novel antibody-drug conjugate (ADC) target in ovarian cancer. CD98hc, encoded by the SLC3A2 gene, is a transmembrane glycoprotein involved in amino acid transport, cell adhesion and signal transduction, among other biological activities. Read More
Veraxa Biotech AG has received scientific advice from the German regulatory authority, the Paul-Ehrlich-Institute (PEI), regarding the underlying biology and proposed nonclinical development plan for its most advanced development program based on its proprietary BiTAC-TCE (bi-targeted tumor-associated cytotoxicity T-cell engager) technology. Read More
Sightera Biosciences BV announced it has raised €3 million (US$3.5 million) in pre-seed funding. The funding will be used to extend the company’s platform technology and asset portfolio, including its lead program in oncology, SIGHT-001. Read More
Teikyo University has synthesized new neutrophil elastase (ELANE; leukocyte elastase) inhibitors potentially useful for the treatment of acute lung injury. Read More
Researchers from Wuhan University and collaborators reported the synthesis and preclinical characterization of NCP07, a novel ERα PROTAC degrader designed to treat endocrine therapy-resistant tumors. Read More
Tyrosinase (TYR) is the key enzyme in melanin synthesis because it catalyzes the first and rate-limiting step of melanin synthesis. TYR inhibitors are used clinically for hyperpigmentation, but there are few direct TYR activators for treating hypopigmentation. Read More
Gan & Lee Pharmaceuticals Co. Ltd. has divulged new molecular glue degraders comprising cereblon (CRBN)-binding agents and casein kinase 1 isoform α (CK1α, CSNK1A1) degradation moieties potentially useful for the treatment of cancer. Read More
Researchers from Ajou University School of Medicine reported the preclinical efficacy of KBN-2201 in a mouse model of late-stage Alzheimer’s disease. Read More
Beijing Sciwind Biotechnology Co. Ltd. and Sciwind Biosciences Co. Ltd. have disclosed new corticotropin-releasing factor CRF2 receptor (CRFH2) agonists potentially useful for the treatment of heart failure, hypertension, obesity, sarcopenia, diabetes and chronic kidney diseases. Read More
Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have reported new dopamine D1 and/or D5 receptor partial agonists. As such, they are reported to be useful for the treatment schizophrenia, attention deficit hyperactivity disorder (ADHD), Tourette disease, sleep disorder, pain, autism spectrum disorder, Parkinson’s and Alzheimer’s disease, among others. Read More
Researchers from the Universities of Bologna and Torino recently presented their hematopoietic stem cell gene therapy (HSC-GT) strategy based on microglia-mediated delivery using a lentiviral vector encoding a secretable, cell-penetrating CDKL5 protein (Igκ-TATk-CDKL5). Read More
